Dr Reddys Laboratories (RDY) Cash & Equivalents (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Cash & Equivalents for 18 consecutive years, with $164.0 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents fell 4.65% year-over-year to $164.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164.0 million (down 4.65% YoY) and the FY2026 annual result came in at $164.0 million, down 4.65% from the prior year.
• Cash & Equivalents fell to $164.0 million in Q1 2026 per RDY's latest filing, from $172.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for RDY reached as high as $761.0 million in Q1 2023 and fell as low as $85.0 million in Q1 2024.
• A 5-year average of $365.0 million and a median of $196.0 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents soared 288.27% — and 2024, when it slumped 88.83%.
• Year by year, Cash & Equivalents stood at $432.0 million in 2022, then jumped by 72.45% to $745.0 million in 2023, then sank by 88.59% to $85.0 million in 2024, then surged by 102.35% to $172.0 million in 2025, then fell by 4.65% to $164.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $164.0 million, $172.0 million, and $85.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.